# Combination antiretroviral therapy: Materials

Source page: https://www.materialinsights.org/technologies/antiretroviral_therapy/tech-materials/

#### Materials it needs

The commodities and chemicals it needs per unit, its share of each one's demand and how critical each is
 Made of

- [API Small-molecule APIs](https://www.materialinsights.org/chemicals/apis/) criticality medium The active drug ingredients are made largely by generic producers in a few countries with pharmaceutical capacity, such as India, Brazil and Thailand ^[4].
 Uses

- [KSM Pharma starting materials and intermediates](https://www.materialinsights.org/chemicals/ksm_intermediates/) criticality medium The active ingredients are built from key starting materials and intermediates bought from fine-chemical makers.
- [Exc Pharmaceutical excipients](https://www.materialinsights.org/chemicals/excipients/) criticality low Fillers and binders turn the active ingredients into tablets, including fixed-dose combinations ^[1].

as of 2026-11-11. No source gives amounts; criticality is the writer's judgement from the concentration of generic production.

#### Critical materials

The materials whose supply could hold it back

- Active ingredients: low prices rest on generic production in a few countries with pharmaceutical capacity, such as India, Brazil and Thailand ^[4].
- Patents: as resistance grows or better drugs arrive, patients must move to newer drugs that are still under patent and cost more ^[4].
- Funding: in 2025, US$ 17.6 billion was available for the AIDS response in low- and middle-income countries, about 20% below the US$ 21.9 billion needed each year by 2030 ^[2].

as of 2026-11-11

#### Sources

1. [Antiretroviral Drug Discovery and Development](https://www.niaid.nih.gov/diseases-conditions/antiretroviral-drug-development) National Institute of Allergy and Infectious Diseases (NIH)
2. [Fact sheet 2026](https://www.unaids.org/sites/default/files/2026-07/2026_UNAIDS_Global_HIV_Factsheet_en.pdf) UNAIDS, 2026
3. [The impact of patents on access to medicines](https://msfaccess.org/impact-patents-access-medicines) MSF Access Campaign (Médecins Sans Frontières), 2017

## Other sections

- [Summary](https://www.materialinsights.org/technologies/antiretroviral_therapy/index.md)
- [Overview](https://www.materialinsights.org/technologies/antiretroviral_therapy/tech-overview/index.md)
- [Science](https://www.materialinsights.org/technologies/antiretroviral_therapy/tech-science/index.md)
- [Evolution](https://www.materialinsights.org/technologies/antiretroviral_therapy/tech-evolution/index.md)
- [Energy footprint](https://www.materialinsights.org/technologies/antiretroviral_therapy/tech-energy-footprint/index.md)
- [Industries](https://www.materialinsights.org/technologies/antiretroviral_therapy/tech-industries/index.md)
